알림

Dyne Therapeutics Inc. (DYN)

NasdaqGS: DYN · 실시간 가격 · USD

26.15

+0.45 (1.75%)

종가 기준: Aug 18, 2026, 11:57 AM

1.75% (1D)

매수호가	n/a
시가총액	4.88B
매출 (ttm)	n/a
순이익 (ttm)	-519.4M
베타	1.08
EPS (ttm)	-3.32
P/E (ttm)	n/a
선행 P/E	-7.83
P/B (ttm)	6.17
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

매도호가	n/a
거래량	1,317,571
평균 거래량 (20일)	2,243,304
시가	25.90
전일 종가	25.70
일중 범위	25.30 - 26.41
52주 범위	11.64 - 27.30
애널리스트	Strong Buy
목표주가	40 (52.96%)
배당	n/a
배당락일	n/a

DYN 소개

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases usin...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 17, 2020

직원 수 289

상장 거래소 NasdaqGS

티커 DYN

웹사이트 https://www.dyne-tx.com

전체 기업 정보

재무 실적

2025년 Dyne Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -446.21M로, 40.58% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 15명의 투자의견을 종합하면 DYN 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 40로, 최근 주가 대비 52.96% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Dyne Therapeutics가 Jul 29, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -1.08 예상치 하회 -0.33, 및 -11.34% 전년 대비 감소.

다음 실적 발표

Dyne Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3주 전 · Simply Wall St.

Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?

Dyne Therapeutics (DYN) is back in focus after pricing an upsized follow on equity offering of 18,300,000 common shares at $20.50 each, raising about $375 million in gross proceeds. See our latest ana...

3주 전 · Zacks

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

3주 전 · MT Newswires

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Major Tech Earnings

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) retreated 0.4%, and the actively

3주 전 · InvestorsHub

Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)

Discounted share sale weighs on stockDyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approxi...

3주 전 · Stocktwits

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.

2 페이지 중 1

Dyne Therapeutics Inc. (DYN)